
Nkarta, Inc. (NKTX) Stock Forecast & Price Target
Nkarta, Inc. (NKTX) Analyst Ratings
Bulls say
Nkarta is showing positive progress in their clinical trials through an increased number of patient enrollments and potential data release in late 2026, which could further de-risk the company's technology. Their unique approach to developing allogeneic NK cell therapies, combined with collaboration opportunities and a strong management team, puts them in a favorable position for success in the competitive biotech landscape. While risks exist, including safety concerns and financing requirements, Nkarta's strong potential for value creation through their platform technology is reflected in their current Buy rating and $14 price target, supported by a discounted cash flow analysis.
Bears say
Nkarta is a clinical-stage biopharmaceutical company with a negative outlook due to the challenges ahead in the form of regulatory approval, the early stage of their clinical programs, and the uncertain success of their drug candidates. Additionally, the high operating expenses and cash burn rate are cause for concern. Despite a potential quick to market strategy, the data from NTrust-1 and NTrust-2 trials may not be enough to fully understand the efficacy and durability of NKX019. Due to these factors, the outlook for Nkarta's stock is negative.
This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.
Nkarta, Inc. (NKTX) Analyst Forecast & Price Prediction
Start investing in Nkarta, Inc. (NKTX)
Order type
Buy in
Order amount
Est. shares
0 shares